Spots Global Cancer Trial Database for chronic lymphocytic leukemia (cll)
Every month we try and update this database with for chronic lymphocytic leukemia (cll) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients | NCT02553304 | Chronic Lymphoc... | 20 Years - | National Health Research Institutes, Taiwan | ||
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | NCT05144347 | Non-Hodgkin's L... Activated B-Cel... Mantle Cell Lym... Chronic Lymphoc... Small Lymphocyt... | XL114 | 18 Years - | Exelixis | |
| Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | NCT03609593 | Chronic Lymphoc... | Bendamustine Venetoclax Rituximab | 18 Years - 99 Years | Columbia University | |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) | NCT01419691 | Chronic Lymphoc... Small Lymphocyt... Leukemia, Proly... | auranofin | 18 Years - | University of Kansas Medical Center | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | NCT05753501 | Hematologic Can... | ABBV-101 | 18 Years - | AbbVie | |
| Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice | NCT03310190 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting | NCT03342144 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | NCT00640523 | Chronic Lymphoc... | forodesine HCl | 18 Years - | BioCryst Pharmaceuticals | |
| Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide | NCT01723839 | Chronic Lymphoc... | Fludarabine, Cy... | 18 Years - | Hackensack Meridian Health | |
| informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia | NCT02582879 | Chronic Lymphoc... | 18 Years - | Pharmacyclics LLC. | ||
| A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies | NCT01705847 | Lymphoid Malign... | GS-9820 | 18 Years - | Gilead Sciences | |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | NCT01050764 | Leukemia, Acute Chronic Myeloge... Myelodysplastic... Non-Hodgkin Lym... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Regulatory T-ce... Conventional T-... Melphalan Thiotepa Fludarabine Anti-thymocyte ... CliniMACS CD34 ... | - 60 Years | Stanford University | |
| Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00230282 | Leukemia B-cell Leukemia Chronic Leukemi... Chronic Lymphoc... | Alemtuzumab Fludarabine Cytoxan | 18 Years - | Stanford University | |
| Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | NCT03588598 | Chronic Lymphoc... Small Lymphocyt... B-Cell Non-Hodg... | SHC014748M | 18 Years - 75 Years | Nanjing Sanhome Pharmaceutical, Co., Ltd. | |
| Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | NCT04419519 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax mono... Venetoclax with... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | NCT01976520 | Chronic Lymphoc... | Oncoquest-CLL v... | 18 Years - | XEME Biopharma Inc. | |
| Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide | NCT01723839 | Chronic Lymphoc... | Fludarabine, Cy... | 18 Years - | Hackensack Meridian Health | |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT01647971 | Non-Hodgkins Ly... B-cell Lymphoma Waldenstrom's M... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... Primary Central... | Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) | NCT01344707 | Advanced Hemato... | 4SC-202 | 18 Years - | 4SC AG | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | NCT02269592 | Monoclonal Gamm... Chronic Lymphoc... Myelodysplastic... Hematological M... B-cell Malignan... Myelodysplastic... IgG Monoclonal ... Smoldering Mult... Waldenstrom Mac... | 18 Years - | Dana-Farber Cancer Institute | ||
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | NCT02200380 | For Donors Related Donors ... For Recipients Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkins Ly... Hodgkins Diseas... Chronic Lymphoc... | CDX-301 CDX-301 and ple... | 18 Years - 70 Years | Celldex Therapeutics | |
| PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | NCT01131247 | Chronic Lymphoc... | ofatumumab + be... | 18 Years - | Nevada Cancer Institute | |
| Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors | NCT03771157 | Chronic Lymphoc... Waldenstrom Mac... | Shingrix vaccin... | 50 Years - | University of Rochester | |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | NCT03406156 | Chronic Lymphoc... Small Lymphocyt... | Obinutuzumab Bendamustine Venetoclax | 18 Years - 99 Years | AbbVie | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | NCT04895436 | Chronic Lymphoc... | Venetoclax Obinutuzumab | 18 Years - | AbbVie | |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | NCT05753501 | Hematologic Can... | ABBV-101 | 18 Years - | AbbVie | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America | NCT02559583 | Multiple Myelom... Leukemia Lymphoid Lymphoma Non-Hodgkin | Chronic Lymphoc... Multiple Myelom... Non-Hodgkin's l... | 18 Years - | Janssen-Cilag Ltd. | |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | NCT05131022 | Chronic Lymphoc... Small Lymphocyt... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenstrom Mac... Primary Central... | NX-5948 | 18 Years - | Nurix Therapeutics, Inc. | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation | NCT04285567 | Chronic Lymphoc... | Obinutuzumab Venetoclax Fludarabine Cyclophosphamid... Rituximab Bendamustine | 18 Years - | Hoffmann-La Roche | |
| Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | NCT00710528 | Chronic Lymphoc... Lymphoma, Non-H... Acute Myeloid L... Multiple Myelom... | CAL-101 | 18 Years - | Gilead Sciences | |
| Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America | NCT02559583 | Multiple Myelom... Leukemia Lymphoid Lymphoma Non-Hodgkin | Chronic Lymphoc... Multiple Myelom... Non-Hodgkin's l... | 18 Years - | Janssen-Cilag Ltd. | |
| Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients | NCT02553304 | Chronic Lymphoc... | 20 Years - | National Health Research Institutes, Taiwan | ||
| Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients | NCT02553304 | Chronic Lymphoc... | 20 Years - | National Health Research Institutes, Taiwan | ||
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | NCT03547115 | Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Chronic Lymphoc... Diffuse Large B... Acute Myeloid L... | voruciclib mono... voruciclib and ... | 18 Years - | MEI Pharma, Inc. | |
| Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma | NCT00614042 | Chronic Lymphoc... Non-Hodgkin's L... | TRU-016 (anti-C... | 18 Years - | Aptevo Therapeutics | |
| Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | NCT01527838 | Non-Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Single FT1050 t... | 18 Years - 65 Years | Fate Therapeutics | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | NCT00664677 | Leukemias Acute Myeloid L... Acute Lymphocyt... Adult T Cell Le... Chronic Myeloid... Chronic Lymphoc... Myelodysplastic... Chronic Myelomo... | Terameprocol (E... | 18 Years - | Erimos Pharmaceuticals | |
| A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01466153 | Chronic Lymphoc... | Rituximab Bendamustine MEDI-551 | 18 Years - 99 Years | MedImmune LLC | |
| B-Cell Hematologic Malignancy Vaccination Registry | NCT02298816 | Monoclonal Gamm... Multiple Myelom... Waldenstrom Mac... Lymphocytosis Lymphoma, Non-H... B-Cell Chronic ... Hematological M... | - | Aurora Health Care | ||
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | NCT05720052 | Relapsed or Ref... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Chronic Lymphoc... Small Lymphocyt... Marginal Zone L... | MS-553 | 18 Years - | MingSight Pharmaceuticals, Inc | |
| Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms | NCT06043011 | Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenström's M... | Routine care as... | 18 Years - | iOMEDICO AG | |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | NCT00001748 | Graft vs Host D... Hematologic Neo... Lymphoma Myelodysplastic... Myeloid Leukemi... | Peripheral bloo... | - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) | NCT01754870 | Chronic Lymphoc... Small Lymphocyt... | Bendamustine an... | 18 Years - | University of Wisconsin, Madison | |
| Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | NCT00640523 | Chronic Lymphoc... | forodesine HCl | 18 Years - | BioCryst Pharmaceuticals | |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | NCT05168930 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Zanubrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | NCT02226861 | Acute Lymphobla... Acute Myelogeno... Chronic Lymphoc... Chronic Myeloge... MDS | CliniMACS CD34 ... ULD IL-2 | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | NCT03400176 | Chronic Lymphoc... | VAY736 ibrutinib | 18 Years - | Novartis | |
| Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) | NCT04758975 | Chronic Lymphoc... | Venetoclax Rituximab Ibrutinib | 18 Years - 65 Years | IRCCS San Raffaele | |
| B-Cell Hematologic Malignancy Vaccination Registry | NCT02298816 | Monoclonal Gamm... Multiple Myelom... Waldenstrom Mac... Lymphocytosis Lymphoma, Non-H... B-Cell Chronic ... Hematological M... | - | Aurora Health Care | ||
| Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) | NCT00923507 | Waldenstrom Mac... Lymphoplasmacyt... Monoclonal B-Ce... Small Lymphocyt... CLL (Chronic Ly... | 18 Years - 110 Years | National Institutes of Health Clinical Center (CC) | ||
| Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | NCT02226861 | Acute Lymphobla... Acute Myelogeno... Chronic Lymphoc... Chronic Myeloge... MDS | CliniMACS CD34 ... ULD IL-2 | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Dietary Intervention With High Phenolic EVOO in CLL | NCT04215367 | Chronic Lymphoc... | High phenolic E... No High phenoli... | 54 Years - 84 Years | University of Peloponnese | |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | NCT01885897 | Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Lymphoma Myeloma Chronic Lymphoc... Chronic Myeloge... | ALT-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | NCT02136511 | Chronic Lymphoc... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | NCT05168930 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Zanubrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| Tumor Registry of Lymphatic Neoplasia | NCT00889798 | Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | 18 Years - | iOMEDICO AG | ||
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| Evaluation of the Immune Restoration Potential Of Lenalidomide | NCT02371577 | Chronic Lymphoc... | Lenalidomide | 18 Years - | University of California, San Diego | |
| The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL | NCT00919321 | Chronic Lymphoc... | Pneumococcal po... | 45 Years - 90 Years | Tampere University Hospital | |
| Expanded Access to Venetoclax | NCT03123029 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu... | Venetoclax | - | AbbVie | |
| Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00694590 | Chronic Lymphoc... Small Lymphocyt... | plerixafor | 18 Years - 80 Years | Sanofi | |
| A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | NCT03085173 | Chronic Lymphoc... Relapsed Refractory | EGFRt/19-28z/4-... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation | NCT04285567 | Chronic Lymphoc... | Obinutuzumab Venetoclax Fludarabine Cyclophosphamid... Rituximab Bendamustine | 18 Years - | Hoffmann-La Roche | |
| Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide | NCT01723839 | Chronic Lymphoc... | Fludarabine, Cy... | 18 Years - | Hackensack Meridian Health | |
| An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | NCT03844048 | Chronic Lymphoc... Acute Myeloid L... Multiple Myelom... Non-Hodgkin's L... Acute Lymphobla... Cancer | Venetoclax | - | AbbVie | |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | NCT04895436 | Chronic Lymphoc... | Venetoclax Obinutuzumab | 18 Years - | AbbVie | |
| Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic Leukemia | NCT04655261 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting | NCT03342144 | Chronic Lymphoc... | 18 Years - | AbbVie | ||
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05105841 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib Obinutuzumab | 20 Years - | AbbVie | |
| Dietary Intervention With High Phenolic EVOO in CLL | NCT04215367 | Chronic Lymphoc... | High phenolic E... No High phenoli... | 54 Years - 84 Years | University of Peloponnese |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
